Results 171 to 180 of about 53,969 (208)

Novel pathogenic ATM mutation with ataxia-telangiectasia in a Chinese family. [PDF]

Front Genet
Zhou Q, Chen M, Tao E.
europepmc   +1 more source

Is high AFP associated with liver diseases in ataxia-telangiectasia and ataxia-oculomotor apraxia? [PDF]

Hepatol Forum
Ismayilov R, Ozum T, Ersal E, Israfilov S, Abdurrahimli N, Cakmakli GY, Elibol B, Balaban HY.   +7 more
europepmc   +1 more source

PARP inhibitor BMN673 triggers PARylation-mediated ATF4-GDF15 pathway to drive autophagy and ferroptosis in ataxia telangiectasia mutated gene-deficient colorectal cancer cells. [PDF]

Mol Biomed
Xiang J, Xu J, Fan H, Chen Q, Lu Y, Wan X, Jiang Y, Zhang X, Zhang C, Liu Q, Ding D, Lei Y.   +11 more
europepmc   +1 more source

Targeting Ataxia Telangiectasia-Mutated and Rad3-Related for Anaplastic Thyroid Cancer. [PDF]

Cancers (Basel)
Lin SF, Hsueh C, Chen WY, Chou TC, Wong RJ.   +4 more
europepmc   +1 more source

Population Pharmacokinetic Modeling and Pediatric Exposure of Dexamethasone Sodium Phosphate Encapsulated in Erythrocytes (eDSP) Administered Monthly for Treatment of Neurological Symptoms of Patients With Ataxia Telangiectasia. [PDF]

CPT Pharmacometrics Syst Pharmacol
Ozdin D, Kheibarshekan L, Mambrini G, Mambrini G, Tremblay PO.   +4 more
europepmc   +1 more source

ATM Expression and Activation in Ataxia Telangiectasia Patients with and without Class Switch Recombination Defects. [PDF]

J Clin Immunol
Salami F, Shad TM, Fathi N, Mojtahedi H, Esmaeili M, Shahkarami S, Afrakoti LGMP, Amirifar P, Delavari S, Nosrati H, Razavi A, Ranjouri MR, Yousefpour M, Esfahani ZH, Azizi G, Ashrafi M, Rezaei N, Yazdani R, Abolhassani H.   +18 more
europepmc   +1 more source

Phase 2a/b randomised placebo-controlled dose-escalation trial of triheptanoin for ataxia-telangiectasia: treating mitochondrial dysfunction with anaplerosis. [PDF]

EBioMedicine
Lynch M, Manoy S, Sly PD, Wainwright CE, Wolvetang E, Feenstra JE, Dowling J, Ware RS, Patel MS, Hermith-Ramirez D, Vogel A, Preece K, Zappala T, Dai S, Webber A, Yeo A, Subramanian G, Rao G, Ma CS, Jose S, Gatei M, Xin B, Sandona N, Lewindon P, Sinclair KG, Nayler S, Lavin MF, Coman DJ.   +27 more
europepmc   +1 more source

Immunodeficiency Diseases and Tumor Immunobiology [PDF]

, 1974
Abramoff, Peter A., Duquesnoy, Rene J.
core   +1 more source

Disruption of ataxia telangiectasia-mutated kinase enhances radiation therapy efficacy in spatially directed diffuse midline glioma models. [PDF]

J Clin Invest
Mangoli A, Valentine V, Maingi SM, Wu SR, Liu HQ, Aksu M, Jain V, Foreman BE, Regal JA, Weidenhammer LB, Stewart CE, Guerra Garcia ME, Hocke E, Abramson K, Michaeli TF, Williams NT, Luo L, Romero M, Deland K, Gadd S, Uchida E, Attardi L, Abe K, Hashizume R, Ashley DM, Becher OJ, Kirsch DG, Gregory SG, Reitman ZJ.   +28 more
europepmc   +1 more source

Safety and Tolerability of Berzosertib, an Ataxia-Telangiectasia-Related Inhibitor, and Veliparib, an Oral Poly (ADP-ribose) Polymerase Inhibitor, in Combination With Cisplatin in Patients With Refractory Solid Tumors. [PDF]

JCO Precis Oncol
O'Sullivan Coyne G, Do KT, Kummar S, Piha-Paul S, Rubinstein L, Kinders R, Parchment RE, Wilsker D, Ferry-Galow K, Miller B, Takebe N, Juwara L, Ong MJ, Bruns A, Hogu M, Naqash AR, Mittra A, Voth AR, Doroshow JH, Chen AP.   +19 more
europepmc   +1 more source